CEimpact

Anticoagulation in Obesity: Rivaroxaban to the Rescue?

Overview / Abstract:	Direct-acting oral anticoagulants have emerged as the preferred anticoagulant class for many patients due to the safety profile, efficacy, and ease of use. However, patients with obesity were excluded from the initial clinical trials raising concerns about external validity for this population. Join us to learn the role of rivaroxaban for stroke and venous thromboembolism prevention in patients with obesity.
Expiration	Mar 10, 2024
Discipline(s)	Pharmacy CPE
Format	Online, Webinar / Webcast / Video
Cost	9.00
Credits / Hours	0.10
Accreditation	ACPE
Presenters / Authors / Faculty	Billie Bartel, PharmD, BCCCP Clinical Pharmacist Sanford Aberdeen Medical Center
Keywords / Search Terms	CEimpact CEimpact CEimpact CEI Impact CEI ce, anticoagulant agents, anticoagulation, chronic kidney disease, journal club, stroke, obesity

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map